Pfizer Inc (PFE)
Receivables turnover
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (ttm) | US$ in thousands | 58,497,000 | 68,538,000 | 77,944,000 | 92,952,000 | 100,331,000 | 100,771,000 | 101,921,000 | 92,738,000 | 81,285,000 | 63,407,000 | 51,332,000 | 44,201,000 | 41,650,000 | 47,096,000 | 47,667,000 | 49,131,000 | 50,098,000 | 51,534,000 | 52,176,000 | 52,443,000 |
| Receivables | US$ in thousands | 11,177,000 | 11,086,000 | 10,231,000 | — | 10,952,000 | — | — | — | 11,479,000 | — | — | — | — | — | — | — | — | — | — | — |
| Receivables turnover | 5.23 | 6.18 | 7.62 | — | 9.16 | — | — | — | 7.08 | — | — | — | — | — | — | — | — | — | — | — |
December 31, 2023 calculation
Receivables turnover = Revenue (ttm) ÷ Receivables
= $58,497,000K ÷ $11,177,000K
= 5.23
The receivables turnover ratio measures how effectively Pfizer Inc. is able to collect outstanding receivables from its customers during a specific period. A higher turnover ratio indicates that the company is efficient in collecting payments from its customers.
Analyzing the trend in Pfizer's receivables turnover ratio over the past eight quarters shows fluctuations. In Q4 2022, Pfizer had a relatively high receivables turnover ratio of 9.16, indicating efficient collection of outstanding receivables. This was followed by a decrease in Q1 2023 to 7.55, but the ratio remained relatively high compared to some previous quarters.
However, in Q2 2023, there was a significant increase in the receivables turnover ratio to 7.62, which was further improved in Q3 2023 to 6.18. This indicates that Pfizer improved its collection efficiency during this period.
In Q4 2023, there was a slight decrease in the receivables turnover ratio to 5.23, which could suggest a potential slowdown in the collection of outstanding receivables compared to the previous quarter.
Overall, Pfizer's receivables turnover ratio has shown fluctuations over the past eight quarters, with some periods of improvement and others of slight decline. It is essential for Pfizer to monitor this ratio consistently to ensure effective management of its accounts receivable and maintain healthy cash flows.
Peer comparison
Dec 31, 2023